Q-omics provides the consensus-scored CCDC148 profile across patient tissues and cancer cell-line models. CCDC148 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CCDC148 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, CCDC148 RNA expression shows 19,106 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KICH, and THYM as cancer lineages where CCDC148 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC148 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC148 survival associations across molecular data types. CCDC148 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC148 RNA expression–survival associations across cancer types. High CCDC148 expression shows unfavorable associations in MESO, DLBC and HNSC, but favorable associations in KIRC, UCEC and BRCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CCDC148 RNA expression.
This table summarizes CCDC148 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CCDC148. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC148 shows lower tumor expression in KICH and KIRC and higher tumor expression in COAD, THCA, PAAD and LIHC. The KICH box plot shows higher CCDC148 RNA expression in normal versus tumor tissue (log2 FC = −2.507, t-test p < 0.001).
This table shows molecular features associated with CCDC148 in patient tissues and cancer cell lines. In patient samples, CCDC148 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC148 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
